710 related articles for article (PubMed ID: 26964808)
1. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
[TBL] [Abstract][Full Text] [Related]
2. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
[TBL] [Abstract][Full Text] [Related]
3. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
4. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
5. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
6. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
[TBL] [Abstract][Full Text] [Related]
7. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
8. A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts.
Nguyen M; Claparols C; Bernadou J; Meunier B
Chembiochem; 2001 Dec; 2(12):877-83. PubMed ID: 11948876
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant.
Zhao X; Yu H; Yu S; Wang F; Sacchettini JC; Magliozzo RS
Biochemistry; 2006 Apr; 45(13):4131-40. PubMed ID: 16566587
[TBL] [Abstract][Full Text] [Related]
10. Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug.
Jena L; Waghmare P; Kashikar S; Kumar S; Harinath BC
Int J Mycobacteriol; 2014 Dec; 3(4):276-82. PubMed ID: 26786627
[TBL] [Abstract][Full Text] [Related]
11. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.
Nguyen M; Quémard A; Broussy S; Bernadou J; Meunier B
Antimicrob Agents Chemother; 2002 Jul; 46(7):2137-44. PubMed ID: 12069966
[TBL] [Abstract][Full Text] [Related]
12. Eosinophil peroxidase oxidizes isoniazid to form the active metabolite against M. tuberculosis, isoniazid-NAD
Babu D; Morgan AG; Reiz B; Whittal RM; Almas S; Lacy P; Siraki AG
Chem Biol Interact; 2019 May; 305():48-53. PubMed ID: 30922765
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach.
Chollet A; Mourey L; Lherbet C; Delbot A; Julien S; Baltas M; Bernadou J; Pratviel G; Maveyraud L; Bernardes-Génisson V
J Struct Biol; 2015 Jun; 190(3):328-37. PubMed ID: 25891098
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites.
Khan SR; Morgan AG; Michail K; Srivastava N; Whittal RM; Aljuhani N; Siraki AG
Biochem Pharmacol; 2016 Apr; 106():46-55. PubMed ID: 26867495
[TBL] [Abstract][Full Text] [Related]
15. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
16. 1H and 13C NMR characterization of hemiamidal isoniazid-NAD(H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis.
Broussy S; Coppel Y; Nguyen M; Bernadou J; Meunier B
Chemistry; 2003 May; 9(9):2034-8. PubMed ID: 12740851
[TBL] [Abstract][Full Text] [Related]
17. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
[TBL] [Abstract][Full Text] [Related]
18. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.
Raghunandanan S; Jose L; Kumar RA
J Antibiot (Tokyo); 2018 Nov; 71(11):939-949. PubMed ID: 30185901
[TBL] [Abstract][Full Text] [Related]
19. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
[TBL] [Abstract][Full Text] [Related]
20. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
